Azetidine, pyrrolidine and piperidine derivatives as 5-HT.sub.1D
receptor agonists
    1.
    发明授权
    Azetidine, pyrrolidine and piperidine derivatives as 5-HT.sub.1D receptor agonists 失效
    氮杂环丁烷,吡咯烷和哌啶衍生物作为5-HT1D受体激动剂

    公开(公告)号:US6127388A

    公开(公告)日:2000-10-03

    申请号:US171929

    申请日:1998-10-26

    CPC分类号: C07D405/14

    摘要: A class of substituted azetidine, pyrrolidine and piperidine derivatives of Formula I are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists. ##STR1##

    摘要翻译: PCT No.PCT / GB97 / 01330 Sec。 371日期:1998年10月26日 102(e)日期1998年10月26日PCT提交1997年5月15日PCT公布。 公开号WO97 / 45426 PCT 日期1997年12月4日一类式I的取代的氮杂环丁烷,吡咯烷和哌啶衍生物是5-HT1样受体的选择性激动剂,是人类5-HT1Dα受体亚型的有效激动剂,同时具有至少10倍的选择性 相对于5-HT1Dβ亚型的5-HT1Dα受体亚型的亲和力; 因此,它们可用于治疗和/或预防临床状况,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起较少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。

    Piperazine, piperidine and tetrahydropyridine derivatives as 5-HT
receptor agonists
    2.
    发明授权
    Piperazine, piperidine and tetrahydropyridine derivatives as 5-HT receptor agonists 失效
    哌嗪,哌啶和四氢吡啶衍生物作为5-HT受体激动剂

    公开(公告)号:US5998416A

    公开(公告)日:1999-12-07

    申请号:US171930

    申请日:1998-10-26

    CPC分类号: C07D405/04 C07D405/14

    摘要: A class of N-substituted piperazine, piperidine, and tetrahydropyridine derivatives, further subltitutedat the 4-position by an optionally substituted alkenyl, alkynyl, aryl-alkyl or heteroaryl-alkyl moiety, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.

    摘要翻译: PCT No.PCT / GB97 / 01329 Sec。 371日期:1998年10月26日 102(e)日期1998年10月26日PCT提交1997年5月15日PCT公布。 出版物WO97 / 45432 PCT 日期1997年12月4日一类N-取代的哌嗪,哌啶和四氢吡啶衍生物,通过任选取代的烯基,炔基,芳基 - 烷基或杂芳基 - 烷基部分进一步在4-位上被取代为5-HT1- 作为人5-HT1Dα受体亚型的有效激动剂,同时相对于5-HT1Dβ亚型对5-HT1Dα受体亚型具有至少10倍的选择性亲和力; 因此,它们可用于治疗和/或预防临床状况,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起较少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。

    Substituted 1-indolylpropyl-4-benzyl-tetrahydropyridine derivatives
    4.
    发明授权
    Substituted 1-indolylpropyl-4-benzyl-tetrahydropyridine derivatives 失效
    取代的1-吲哚基丙基-4-苄基 - 四氢吡啶衍生物

    公开(公告)号:US5994374A

    公开(公告)日:1999-11-30

    申请号:US068631

    申请日:1998-05-08

    摘要: A class of 1-[3-(1H-indol-3-yl)propyl]-4-benzyl-1,2,5,6-tetrahydropyridine derivatives, substituted at the 5-position of the indole nucleus by a 1,2,4-triazol-4-yl moiety, and on the methylene linkage of the benzyl moiety by an alkyl, alkoxy, or alkoxy-alkoxy substituent, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype while possessing at least a 10-fold selective affinity for the 5HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype. They are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D.alpha. receptors is indicated, and are expected to have fewer undesirable cardiovascular and other side effects.

    摘要翻译: PCT No.PCT / GB96 / 02684。 371日期1998年5月8日 102(e)日期1998年5月8日PCT 1996年11月4日PCT PCT。 公开号WO97 / 17337 日期1997年5月15日一类在吲哚核的5-位被取代的1- [3-(1H-吲哚-3-基)丙基] -4-苄基-1,2,5,6-四氢吡啶衍生物 1,2,4-三唑-4-基部分,并且在烷基,烷氧基或烷氧基 - 烷氧基取代基上的苄基部分的亚甲基键是5-HT1样受体的选择性激动剂,其为 人类5-HT1Dα受体亚型,而对5HT1Dα受体亚型相对于5-HT1Dβ亚型具有至少10倍的选择性亲和力。 因此,它们可用于治疗和/或预防临床症状,特别是偏头痛和相关疾病,其中指出5-HT1Dα受体的亚型选择性激动剂,并且预期具有较少的不期望的心血管和其它副作用 。

    Aminocyclohexane derivatives as 5-HT receptor agonists
    5.
    发明授权
    Aminocyclohexane derivatives as 5-HT receptor agonists 失效
    氨基环己烷衍生物作为5-HT受体激动剂

    公开(公告)号:US06211219B1

    公开(公告)日:2001-04-03

    申请号:US09214343

    申请日:1999-01-04

    IPC分类号: C07D40306

    摘要: A class of substituted aminocyclohexane derivatives are selective agonists of 5-HT1-like receptors, being potent agonists of the human 5-HT1D&agr; receptor subtype while possessing at least a 10-fold selective affinity for the 5-HT1D&agr; receptor subtype relative to the 5-HT1D&bgr; subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.

    摘要翻译: 一类取代的氨基环己烷衍生物是5-HT1样受体的选择性激动剂,它是人类5-HT1Dalpha受体亚型的有效激动剂,同时对5-HT1Dalpha受体亚型具有至少10倍的选择性亲和力, HT1Dbeta亚型; 因此,它们可用于治疗和/或预防临床症状,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起更少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。

    Substituted 1-indolylpropyl-4-phenethylpiperazadine derivatives
    9.
    发明授权
    Substituted 1-indolylpropyl-4-phenethylpiperazadine derivatives 失效
    取代的1-吲哚丙基-4-苯乙基哌嗪衍生物

    公开(公告)号:US5889008A

    公开(公告)日:1999-03-30

    申请号:US11308

    申请日:1998-02-05

    摘要: A class of 1-�3-(1H-indol-3-yl)propyl!-4-(2-phenylethyl) piperazine derivatives, substituted at the 5-position of the indole nucleus by a five-membered heteroaromatic moiety, and on the phenyl ring of the phenethyl moiety by fluoro, chloro, trifluoromethyl, alkoxy or an oxazolidinone group and optionally by one or two further substituents, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D .alpha. receptor subtype while possessing at least a 10-fold selective affinity for the 5-HT.sub.1D .alpha. receptor subtype relative to the 5-HT.sub.1D .alpha. subtype; they are therefore usefull in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.

    摘要翻译: PCT No.PCT / GB96 / 01806 Sec。 371日期:1998年2月5日 102(e)1998年2月5日PCT PCT 1996年7月29日PCT公布。 公开号WO97 / 06159 日期1997年2月20日一类1- [3-(1H-吲哚-3-基)丙基] -4-(2-苯基乙基)哌嗪衍生物,其在吲哚核的5位被五元 氟代,氯代,三氟甲基,烷氧基或恶唑烷酮基以及任选地被一个或两个另外的取代基组成的苯乙基部分的苯环是5-HT1样受体的选择性激动剂,是人类的有效激动剂 5-HT1Dα受体亚型,同时相对于5-HT1Dα亚型对5-HT1Dα受体亚型具有至少10倍的选择性亲和力; 因此,它们可用于治疗和/或预防临床状况,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起更少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。